Search

Your search keyword '"Pinto, Antonello"' showing total 232 results
Start Over Author "Pinto, Antonello"
232 results on '"Pinto, Antonello"'

1. Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside

Author

Fedele, Palma, primary, Santoro, Anna Natalizia, additional, Pini, Francesca, additional, Pellegrino, Marcello, additional, Polito, Giuseppe, additional, De Luca, Maria Chiara, additional, Pignatelli, Antonietta, additional, Tancredi, Michele, additional, Lagattolla, Valeria, additional, Anglani, Alessandro, additional, Guarini, Chiara, additional, Pinto, Antonello, additional, and Bracciale, Pietro, additional

Published
2024
Full Text
View/download PDF

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

4. Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.

Author

Fedele, Palma, Landriscina, Matteo, Moraca, Lucia, Cusmai, Antonio, Gnoni, Antonio, Licchetta, Antonella, Guarini, Chiara, Lanotte, Laura, Pappagallo, Maria Nicla, Melaccio, Assunta, Giordano, Guido, Maselli, Felicia Maria, Pinto, Antonello, Giuliani, Francesco, Chiuri, Vincenzo, Giotta, Francesco, and Gadaleta-Caldarola, Gennaro

Abstract

Simple Summary: This study explores the effectiveness and safety of a common breast cancer treatment in elderly patients, a group often overlooked in clinical trials. Specifically, it focuses on using CDK4/6 inhibitors with hormone therapy for treating metastatic HR+/HER2- breast cancer in patients aged 70 and older. This research aims to understand how well this treatment works and how tolerable it is for this vulnerable population, which faces unique challenges due to age and other health conditions. The results of this study may provide valuable insights for clinicians, enabling more informed treatment decisions which optimize therapeutic outcomes and enhance the quality of life for elderly patients with breast cancer. Background: Metastatic HR+/HER2- breast cancer is commonly treated with CDK4/6 inhibitors in combination with endocrine therapy. However, the efficacy and safety of this approach in elderly patients (≥70 years) remain unclear, particularly in the context of real-world clinical practice. This study aims to evaluate the clinical outcomes and tolerability of CDK4/6 inhibitor treatments in this fragile population, which is often under-represented in randomized clinical trials. Patients and methods: This retrospective multicenter study included elderly patients with metastatic HR+/HER2-negative breast cancer receiving first-line CDK4/6 inhibitors. The primary endpoint was progression-free survival (PFS). The secondary endpoints focused on the overall survival (OS), safety, and tolerability, considering variables such as tumor subtype, age, comorbidities, and treatment specifics. Results: The median PFS and OS were slightly lower than those reported in clinical trials, reflecting the inclusion of a more fragile population. The luminal B subtype was linked to a poorer PFS, while other factors like age, BMI, and ECOG status did not significantly affect the outcomes. A safety analysis indicated a higher incidence of grade 3 or higher toxicities, especially in frail patients, leading to dose reductions. Despite these challenges, CDK4/6 inhibitors were generally well-tolerated, allowing most patients to continue therapy. Conclusions: CDK4/6 inhibitors with endocrine therapy are effective in elderly patients with metastatic HR+/HER2- breast cancer, though careful management is crucial to balance efficacy and minimize adverse events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy.

Author

Pinto, Antonello, Guarini, Chiara, Giampaglia, Marianna, Sanna, Valeria, Melaccio, Assunta, Lanotte, Laura, Santoro, Anna Natalizia, Pini, Francesca, Cusmai, Antonio, Giuliani, Francesco, Gadaleta-Caldarola, Gennaro, and Fedele, Palma

Subjects
*TREATMENT effectiveness, *BREAST cancer, *CANCER treatment, *IMMUNE system, *CANCER cells, *BREAST
Abstract

The advent of immunotherapy and antibody–drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However, challenges, such as resistance and limited efficacy in certain cases, remain. Recently, the combination of these therapies has emerged as a promising approach to address these challenges. ADCs play a crucial role by delivering cytotoxic agents directly to breast cancer cells, minimizing damage to healthy tissue and enhancing the tumor-killing effect. Concurrently, immunotherapies harness the body's immune system to recognize and eliminate cancer cells. This integration offers potential to overcome resistance mechanisms and significantly improve therapeutic outcomes. This review explores the rationale behind combining immunotherapies with ADCs, recent advances in this field, and the potential implications for breast cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, Carlo, Marcheselli, Luigi, Mina, Roberto, Sassone, Marianna, Guidetti, Anna, Penna, Domenico, Cattaneo, Chiara, Bonuomo, Valentina, Busca, Alessandro, Ferreri, Andrés José María, Bruna, Riccardo, Petrucci, Luigi, Cairoli, Roberto, Salvini, Marco, Bertù, Lorenza, Ladetto, Marco, Pilerci, Sofia, Pinto, Antonello, Ramadan, Safaa, Marchesi, Francesco, Cavo, Michele, Arcaini, Luca, Coviello, Elisa, Romano, Alessandra, Musto, Pellegrino, Massaia, Massimo, Fracchiolla, Nicola, Marchetti, Monia, Scattolin, Annamaria, Tisi, Maria Chiara, Cuneo, Antonio, Della Porta, Matteo, Trentin, Livio, Turrini, Marco, Gherlinzoni, Filippo, Tafuri, Agostino, Galimberti, Sara, Bocchia, Monica, Cardinali, Valeria, Cilloni, Daniela, Corso, Alessandro, Armiento, Daniele, Rigacci, Luigi, La Barbera, Elettra Ortu, Gambacorti-Passerini, Carlo, Visani, Giuseppe, Vallisa, Daniele, Venditti, Adriano, Selleri, Carmine, Conconi, Annarita, Tosi, Patrizia, Lanza, Francesco, Candoni, Anna, Krampera, Mauro, Corradini, Paolo, Passamonti, Francesco, and Merli, Francesco

Published
2022
Full Text
View/download PDF

7. 1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

Author

Talpin, Alice, primary, Kervevan, Jerome, additional, Aubergeon, Lucie, additional, Maia, Ana, additional, Blanc, Tifanny Mersceman, additional, Bachrouche, Diana, additional, Ventujol, Chloé, additional, Bernard, Léa, additional, Manteau, Amandine, additional, Gouttefangeas, Cecile, additional, Villasboas, Jose, additional, Pinto, Antonello, additional, Bosch, Francesc, additional, García-Sanz, Ramon, additional, Garcia, Carlos Grande, additional, Smith, Stephen D, additional, Arcaini, Luca, additional, Merryman, Reid, additional, Friedberg, Jonathan W, additional, Ansell, Stephen, additional, Armand, Philippe, additional, Zinzani, Pier, additional, Bonny, Christophe, additional, Chene, Laurent, additional, and Magalhaes, Joao Gamelas, additional

Published
2023
Full Text
View/download PDF

8. HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma

Author

Bergamo, Lodovico Terzi di, Pirosa, Maria Cristina, Bruscaggin, Alessio, Salehi, Matin, Spina, Valeria, Pini, Katia, Bocchetta, Simone, Giordano, Claudia, Condouci, Adalgisa, Forestieri, Gabriela, Piffaretti, Deborah, de Almeida, Joyce Marques, Annunziata, Salvatore, Bergesio, Fabrizio, Borsatti, Eugenio, Bulian, Pietro, Chauvie, Stephane, Cuzzocrea, Marco, Trani, Martina Di, Gerber, Bernhard, Kurlapski, Michal, Moccia, Alden, Moia, Riccardo, Rinaldi, Andrea, Rodari, Marcello, Romanowicz, Grzegorz, Sacchetti, Gian Mauro, Stasia, Alessandra, Stathis, Anastasios, Stuessi, Georg, Zangrilli, Ilaria, Larocca, Luigi Maria, Pinto, Antonello, Santoro, Armando, Cavalli, Franco, Zucca, Emanuele, Gattei, Valter, Zaucha, Jan Maciej, Stella, Carmelo Carlo, Hohaus, Stefan, Gaidano, Gianluca, Ceriani, Luca, and Rossi, Davide

Published
2022
Full Text
View/download PDF

9. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Author

Facon, Thierry, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John V., Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J., Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D., Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darrell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C., Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, and Hulin, Cyrille

Published
2018
Full Text
View/download PDF

10. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Author

Gotti, Manuel, primary, Sciarra, Roberta, additional, Pulsoni, Alessandro, additional, Merli, Francesco, additional, Luminari, Stefano, additional, Zerbi, Caterina, additional, Trentin, Livio, additional, Re, Alessandro, additional, Rusconi, Chiara, additional, Viviani, Simonetta, additional, Rossi, Andrea, additional, Cocito, Federica, additional, Botto, Barbara, additional, Meli, Erika, additional, Pinto, Antonello, additional, Dogliotti, Irene, additional, Gini, Guido, additional, Puccini, Benedetta, additional, Ricci, Francesca, additional, Nassi, Luca, additional, Fabbri, Alberto, additional, Liberati, Anna Marina, additional, Merli, Michele, additional, Filippi, Andrea Riccardo, additional, Bonfichi, Maurizio, additional, Zoboli, Valentina, additional, Tartaglia, Germana, additional, Annechini, Giorgia, additional, D’Elia, Gianna Maria, additional, Del Giudice, Ilaria, additional, Alvarez, Isabel, additional, Visentin, Andrea, additional, Pravato, Stefano, additional, Dalceggio, Daniela, additional, Pagani, Chiara, additional, Ferrari, Silvia, additional, Cristinelli, Caterina, additional, Lazic, Tanja, additional, Ferretti, Virginia Valeria, additional, Ricardi, Umberto, additional, and Arcaini, Luca, additional

Published
2023
Full Text
View/download PDF

11. Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma

Author

Bergamo, Lodovico Terzi di, primary, Pirosa, Maria Cristina, additional, Bruscaggin, Alessio, additional, Salehi, Matin, additional, Spina, Valeria, additional, Pini, Katia, additional, Bocchetta, Simone, additional, Giordano, Claudia, additional, Condouci, Adalgisa, additional, Forestieri, Gabriela, additional, Piffaretti, Deborah, additional, de Almeida, Joyce Marques, additional, Annunziata, Salvatore, additional, Bergesio, Fabrizio, additional, Borsatti, Eugenio, additional, Bulian, Pietro, additional, Chauvie, Stephane, additional, Cuzzocrea, Marco, additional, Trani, Martina Di, additional, Gerber, Bernhard, additional, Kurlapski, Michal, additional, Moccia, Alden, additional, Moia, Riccardo, additional, Rinaldi, Andrea, additional, Rodari, Marcello, additional, Romanowicz, Grzegorz, additional, Sacchetti, Gian Mauro, additional, Stasia, Alessandra, additional, Stathis, Anastasios, additional, Stuessi, Georg, additional, Zangrilli, Ilaria, additional, Larocca, Luigi Maria, additional, Pinto, Antonello, additional, Santoro, Armando, additional, Cavalli, Franco, additional, Zucca, Emanuele, additional, Gattei, Valter, additional, Zaucha, Jan Maciej, additional, Stella, Carmelo Carlo, additional, Hohaus, Stefan, additional, Gaidano, Gianluca, additional, Ceriani, Luca, additional, and Rossi, Davide, additional

Published
2022
Full Text
View/download PDF

12. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Author

Ladetto, Marco, Lobetti-Bodoni, Chiara, Mantoan, Barbara, Ceccarelli, Manuela, Boccomini, Carola, Genuardi, Elisa, Chiappella, Annalisa, Baldini, Luca, Rossi, Giuseppe, Pulsoni, Alessandro, Di Raimondo, Francesco, Rigacci, Luigi, Pinto, Antonello, Galimberti, Sara, Bari, Alessia, Rota-Scalabrini, Delia, Ferrari, Angela, Zaja, Francesco, Gallamini, Andrea, Specchia, Giorgina, Musto, Pellegrino, Rossi, Francesca Gaia, Gamba, Enrica, Evangelista, Andrea, and Vitolo, Umberto

Published
2013
Full Text
View/download PDF

13. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

14. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen

Author

Musso, Maurizio, Messina, Giuseppe, Di Renzo, Nicola, Di Carlo, Paolo, Vitolo, Umberto, Scalone, Renato, Marcacci, Gianpaolo, Scalzulli, Potito R., Moscato, Tiziana, Matera, Rossella, Crescimanno, Alessandra, Santarone, Stella, Orciuolo, Enrico, Merenda, Anxur, Pavone, Vincenzo, Pastore, Domenico, Donnarumma, Daniela, Carella, Angelo M., Ciochetto, Chiara, Cascavilla, Nicola, Mele, Anna, Lanza, Francesco, Di Nicola, Massimo, Bonizzoni, Erminio, and Pinto, Antonello

Published
2016
Full Text
View/download PDF

15. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS

Author

Stefoni, Vittorio, Marangon, Miriam, Re, Alessandro, Lleshi, Arben, Bonfichi, Maurizio, Pinto, Antonello, Bianchetti, Nicola, Pellegrini, Cinzia, Argnani, Lisa, Zinzani, Pier Luigi, Stefoni, Vittorio, Marangon, Miriam, Re, Alessandro, Lleshi, Arben, Bonfichi, Maurizio, Pinto, Antonello, Bianchetti, Nicola, Pellegrini, Cinzia, Argnani, Lisa, and Zinzani, Pier Luigi

Subjects
brentuximab vedotin, Hodgkin's Lymphoma, Cell Therapy and Immunotherapy, elderly
Abstract

NA

Published
2020

16. Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Author

Chiappella, Annalisa, primary, Carniti, Cristiana, additional, Re, Alessandro, additional, Castellino, Claudia, additional, Evangelista, Andrea, additional, Tabanelli, Valentina, additional, Ciancia, Rosanna, additional, Orsucci, Lorella, additional, Pinto, Antonello, additional, Usai, Sara Veronica, additional, Arcari, Annalisa, additional, Ilariucci, Fiorella, additional, Rossi, Francesca Gaia, additional, Benedetti, Fabio, additional, Flenghi, Leonardo, additional, Ghiggi, Chiara, additional, Molinari, Anna Lia, additional, Stefoni, Vittorio, additional, Volpetti, Stefano, additional, Zilioli, Vittorio Ruggero, additional, Ballerini, Filippo, additional, Bruna, Riccardo, additional, Cavallo, Federica, additional, Musuraca, Gerardo, additional, Patti, Caterina, additional, Re, Francesca, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Zanni, Manuela, additional, Dodero, Anna, additional, Pileri, Stefano A, additional, Ciccone, Giovannino, additional, and Corradini, Paolo, additional

Published
2021
Full Text
View/download PDF

17. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Author

Luminari, Stefano, primary, Nizzoli, Maria Elena, additional, Chiarenza, Annalisa, additional, Mannina, Donato, additional, Tucci, Alessandra, additional, Boccomini, Carola, additional, Farina, Lucia, additional, Olivieri, Jacopo, additional, Marcheselli, Luigi, additional, Ferrero, Simone, additional, Arcaini, Luca, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Califano, Catello, additional, Merli, Michele, additional, Bari, Alessia, additional, Conconi, Annarita, additional, Re, Francesca, additional, Balzarotti, Monica, additional, Ladetto, Marco, additional, Patti, Caterina, additional, Pinto, Antonello, additional, Cabras, Maria Giuseppina, additional, Musto, Pellegrino, additional, Gini, Guido, additional, Arcari, Annalisa, additional, Manni, Martina, additional, Versari, Annibale, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

20. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Author

Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, and Facon, Thierry

Published
2014
Full Text
View/download PDF

21. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma

Author

Russo, Filippo, Corazzelli, Gaetano, Frigeri, Ferdinando, Capobianco, Gaetana, Aloj, Luigi, Volzone, Francesco, De Chiara, Annarosaria, Bonelli, Annamaria, Gatani, Tindaro, Marcacci, Gianpaolo, Donnarumma, Daniela, Becchimanzi, Cristina, de Lutio, Elisabetta, Ionna, Franco, De Filippi, Rosaria, Lastoria, Secondo, and Pinto, Antonello

Published
2014
Full Text
View/download PDF

22. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial

Author

Gallamini, Andrea, Zaja, Francesco, Patti, Caterina, Billio, Atto, Specchia, Maria Rosaria, Tucci, Alessandra, Levis, Alessandro, Manna, Annunziata, Secondo, Vicenzo, Rigacci, Luigi, Pinto, Antonello, Iannitto, Emilio, Zoli, Valerio, Torchio, Pierfederico, Pileri, Stefano, and Tarella, Corrado

Published
2007
Full Text
View/download PDF

24. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas

Author

Franco, Renato, Scognamiglio, Giosuè, Valentino, Elena, Vitiello, Michela, Luciano, Antonio, Palma, Giuseppe, Arra, Claudio, La Mantia, Elvira, Panico, Luigi, Tenneriello, Valentina, Pinto, Antonello, Frigeri, Ferdinando, Capobianco, Gaetana, Botti, Gerardo, Cerchia, Laura, De Chiara, Annarosaria, Fedele, Monica, Franco, Renato, Scognamiglio, Giosuè, Valentino, Elena, Vitiello, Michela, Luciano, Antonio, Palma, Giuseppe, Arra, Claudio, La Mantia, Elvira, Panico, Luigi, Tenneriello, Valentina, Pinto, Antonello, Frigeri, Ferdinando, Capobianco, Gaetana, Botti, Gerardo, Cerchia, Laura, De Chiara, Annarosaria, and Fedele, Monica

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Pathology, Vincristine, PATZ1, Cell of origin, Kruppel-Like Transcription Factors, Cohort Studies, Surgical pathology, Mice, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, tissue-microarray, hemic and lymphatic diseases, Internal medicine, medicine, Animals, Humans, Retrospective Studies, bcl-2-Associated X Protein, Mice, Knockout, B-Lymphocytes, Hematology, business.industry, Tumor Suppressor Proteins, non-Hodgkin lymphoma, Germinal center, Germinal Center, BCL6, Survival Analysis, 3. Good health, Gene Expression Regulation, Neoplastic, Repressor Proteins, Transplantation, Treatment Outcome, 030104 developmental biology, non-Hodgkin lymphomas, DLBCL, 030220 oncology & carcinogenesis, Proto-Oncogene Proteins c-bcl-6, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, prognostic marker, Research Paper, medicine.drug
Abstract

// Renato Franco 1, 2, * , Giosue Scognamiglio 1, * , Elena Valentino 1 , Michela Vitiello 3 , Antonio Luciano 4 , Giuseppe Palma 4 , Claudio Arra 4 , Elvira La Mantia 1 , Luigi Panico 5 , Valentina Tenneriello 5 , Antonello Pinto 6 , Ferdinando Frigeri 6 , Gaetana Capobianco 6 , Gerardo Botti 1 , Laura Cerchia 3 , Annarosaria De Chiara 1 , Monica Fedele 3 1 Surgical Pathology Unit, National Cancer Institute ‘Fondazione Giovanni Pascale’, IRCCS, Naples, Italy 2 Pathology Unit, Second University of Naples, Naples, Italy 3 Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), Naples, Italy 4 Animal Facility, National Cancer Institute ‘Fondazione Giovanni Pascale’, IRCCS, Naples, Italy 5 Pathology Unit, Hospital ‘S.G. Moscati’, Avellino, Italy 6 Haematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy * These authors share co-first authorship Correspondence to: Monica Fedele, email: mfedele@unina.it , monica.fedele@cnr.it Renato Franco, email: renato.franco@unina2.it , renfr@yahoo.com Keywords: non-Hodgkin lymphomas, prognostic marker, PATZ1, tissue-microarray, DLBCL Received: January 16, 2016 Accepted: July 18, 2016 Published: August 01, 2016 ABSTRACT Non-Hodgkin lymphomas (NHLs) include a heterogeneous group of diseases, which differ in both cellular origin and clinical behavior. Among the aggressive malignancies of this group, the diffuse large B-cell lymphomas (DLBCLs) are the most frequently observed. They are themselves clinically and molecularly heterogeneous and have been further sub-divided in three sub-types according to different cell of origin, mechanisms of oncogenesis and clinical outcome. Among them, the germinal center B-cell-like (GCB) derives from the germinal center and expresses the BCL6 oncogene. We have previously shown that Patz1-knockout mice develop B-cell neoplasias, suggesting a tumor suppressor role for PATZ1 in human NHLs. Here, by immunohistochemical analysis of a tissue-microarray including 170 NHLs, we found that PATZ1 nuclear expression is down-regulated in follicular lymphomas and DLBCLs. Moreover, consistent with our previous results showing a PATZ1-dependent regulation of BCL6 and BAX transcription, we show that low PATZ1 nuclear expression significantly correlates with high BCL6 expression, mainly in DLBCLs, and with low BAX expression, also considering separately follicular lymphomas and DLBCLs. Finally, by analyzing overall and progression-free survival in DLBCL patients that underwent rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, low levels of PATZ1 were significantly associated to a worst outcome and demonstrated an independent prognostic factor in multivariate analysis, including known prognostic factors of DLBCL, IPI score and cell of origin (GCB/non-GCB). Therefore, we propose PATZ1 as a new prognostic marker of DLBCLs, which may act as a tumor suppressor by enhancing apoptosis through inhibiting and enhancing transcription of BCL6 and BAX, respectively.

Published
2016

26. HODGKIN LYMPHOMA THERAPY - Cessione una tantum, irrevocabile ed in via esclusiva a Mundipharma EDO GmbH/PURDUE del proprio diritto di titolarità al brevetto, domanda nr. US 2018/0098969A1 la cui procedura di concessione è tuttora in itinere e dove la sottoscritta compare tra i co-inventori

Author

MEHRLING THOMAS, DE FILIPPI ROSARIA, PINTO ANTONELLO, Mehrling, Thoma, DE FILIPPI, Rosaria, and Pinto, Antonello

Subjects
HODGKIN LYMPHOMA, TREATMENT, COMBINATION
Abstract

There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: I, a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination

Published
2018

28. Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Author

Casulo, Carla, primary, Santoro, Armando, additional, Ando, Kiyoshi, additional, Le Gouill, Steven, additional, Ruan, Jia, additional, Radford, John, additional, Arcaini, Luca, additional, Pinto, Antonello, additional, Bouabdallah, Reda, additional, Izutsu, Koji, additional, Rule, Simon, additional, Munoz, Javier, additional, Casadebaig, Marie-Laure, additional, Fox, Brian, additional, Rettby, Nils, additional, Dell'Aringa, Justine, additional, Delarue, Richard, additional, Newhall, Kathryn, additional, Czuczman, Myron, additional, and Cartron, Guillaume, additional

Published
2019
Full Text
View/download PDF

29. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.

Author

Zinzani, Pier Luigi, Bregni, Marco, Spione, Mario, Mitterer, Manfred, Musuraca, Gerardo, Bugli, Annamaria, Piazza, Francesco, and Pinto, Antonello

Subjects
DIFFUSE large B-cell lymphomas, MEDICAL personnel, CARDIOTOXICITY
Abstract

Introduction: Treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) represents a challenge for clinicians due to the lack of therapeutic options. DLBCL is not a rare disease in Italy. Pixantrone is an aza-anthracenedione, which, when compared to anthracyclines and anthracenediones, has a significantly reduced cardiotoxicity while maintaining good anti-tumor activity. However, the evidence on the use of pixantrone in the context of daily clinical practice is scarce. Methods: We focused on the Italian patient subset of a larger European retrospective study (the PIXA Registry) to assess the efficacy and safety of pixantrone in a real-life DLBCL population. The molecular profile of the disease and its impact on drug efficacy were also assessed. Results: Fifteen heavily pretreated DLBCL patients (13 males and 2 females) underwent treatment with pixantrone for a median of 2 cycles (range 1–6). Eight patients were bcl2 positive, 7 bcl6 positive, and 4 myc positive; 4 patients were diagnosed as double-hit, and 2 as triple-hit DLBCL. The overall response rate was 26.7% with a best response rate of 46.7%. Three patients had grade IV adverse events, which caused drug discontinuation. Four patients had 5 cases of grade III toxicities (1 thrombocytopenia, 1 stomatitis, and 3 neutropenia). One mild cardiac toxicity (sinus tachycardia for which no action was required) was possibly related to the study drug. Conclusion: Our data documented drug efficacy that is satisfactory for this high-risk subset of patients with an acceptable toxicity profile. Results indicate that pixantrone could be a significant treatment option in patients with R/R aggressive DLBCL treated in everyday clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

Author

Broccoli, Alessandro, Pellegrini, Cinzia, Di Rocco, Alice, Puccini, Benedetta, Patti, Caterina, Gini, Guido, Mannina, Donato, Tani, Monica, Rusconi, Chiara, Romano, Alessandra, Vanazzi, Anna, Botto, Barbara, Carlo-Stella, Carmelo, Hohaus, Stefan, Musto, Pellegrino, Mazza, Patrizio, Molica, Stefano, Corradini, Paolo, Fama, Angelo, Gaudio, Francesco, Merli, Michele, Gravetti, Angela, Gritti, Giuseppe, Arcari, Annalisa, Tosi, Patrizia, Liberati, Anna Marina, Pinto, Antonello, Pavone, Vincenzo, Gherlinzoni, Filippo, Naso, Virginia, Volpetti, Stefano, Trentin, Livio, Goldaniga, Maria Cecilia, Bonfichi, Maurizio, De Renzo, Amalia, Schiavotto, Corrado, Spina, Michele, Storti, Sergio, Carella, Angelo Michele, Stefoni, Vittorio, Argnani, Lisa, Zinzani, Pier Luigi, Hohaus, Stefan (ORCID:0000-0002-5534-7197), Storti, Sergio (ORCID:0000-0002-4374-3985), Broccoli, Alessandro, Pellegrini, Cinzia, Di Rocco, Alice, Puccini, Benedetta, Patti, Caterina, Gini, Guido, Mannina, Donato, Tani, Monica, Rusconi, Chiara, Romano, Alessandra, Vanazzi, Anna, Botto, Barbara, Carlo-Stella, Carmelo, Hohaus, Stefan, Musto, Pellegrino, Mazza, Patrizio, Molica, Stefano, Corradini, Paolo, Fama, Angelo, Gaudio, Francesco, Merli, Michele, Gravetti, Angela, Gritti, Giuseppe, Arcari, Annalisa, Tosi, Patrizia, Liberati, Anna Marina, Pinto, Antonello, Pavone, Vincenzo, Gherlinzoni, Filippo, Naso, Virginia, Volpetti, Stefano, Trentin, Livio, Goldaniga, Maria Cecilia, Bonfichi, Maurizio, De Renzo, Amalia, Schiavotto, Corrado, Spina, Michele, Storti, Sergio, Carella, Angelo Michele, Stefoni, Vittorio, Argnani, Lisa, Zinzani, Pier Luigi, Hohaus, Stefan (ORCID:0000-0002-5534-7197), and Storti, Sergio (ORCID:0000-0002-4374-3985)

Abstract

Between November 2012 and July 2014, in accordance with national law 648/96, brentuximab vedotin was available in Italy for patients with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context. A large Italian observational retrospective study was conducted on the use of brentuximab vedotin in everyday clinical practice to check whether clinical trial results are confirmed in a real-life context. The primary endpoint of this study was best response; secondary endpoints were the overall response rate at the end of the treatment, duration of response, survival and safety profile. A total of 40 heavily pretreated patients were enrolled. Best response was observed after a median of four cycles in 77.5%: globally, 47.5% patients obtained a complete response, 64.2% in the elderly subset. The overall response rate was 62.5%. At the latest follow up, 15/18 patients are still in complete remission (3 with consolidation). The progression-free survival rate at 24 months was 39.1% and the disease-free survival rate at the same time was 54% (median not reached). All the long-term responders were aged <30 years at first infusion. The treatment was well tolerated even in this real-life context and no deaths were linked to drug toxicity. Brentuximab vedotin induces clinical responses quite rapidly, i.e. within the first four cycles of treatment in most responders, thus enabling timely use of transplantation. For patients ineligible for transplant or for those in whom a transplant procedure failed, brentuximab vedotin may represent a feasible effective therapeutic option in everyday clinical practice.

Published
2017

32. Final analysis of overall survival from the first trial

Author

Facon, Thierry Dimopoulos, Meletios A. Dispenzieri, Angela and Catalano, John V. Belch, Andrew Cavo, Michele Pinto, Antonello Weisel, Katja Ludwig, Heinz Bahlis, Nizar J. and Banos, Anne Tiab, Mourad Delforge, Michel Cavenagh, Jamie D. and Geraldes, Catarina Lee, Je-Jung Chen, Christine Oriol, Albert De La Rubia, Javier White, Darrell Binder, Daniel and Lu, Jin Anderson, Kenneth C. Moreau, Philippe Attal, Michel and Fermand, Jean-Paul Avet-Loiseau, Herve Ervin-Haynes, Annette and Chen, Guang Houck, Vanessa Hulin, Cyrille Benboubker, Lofti

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2016

33. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

Author

Broccoli, Alessandro, primary, Pellegrini, Cinzia, additional, Di Rocco, Alice, additional, Puccini, Benedetta, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Carlo-Stella, Carmelo, additional, Hohaus, Stefan, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Gravetti, Angela, additional, Gritti, Giuseppe, additional, Arcari, Annalisa, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Naso, Virginia, additional, Volpetti, Stefano, additional, Trentin, Livio, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Storti, Sergio, additional, Carella, Angelo Michele, additional, Stefoni, Vittorio, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2017
Full Text
View/download PDF

34. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma

Author

Pellegrini, Cinzia, primary, Broccoli, Alessandro, additional, Pulsoni, Alessandro, additional, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Santoro, Armando, additional, Hoaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Ronconi, Fioravante, additional, Gritti, Giuseppe, additional, Vallisa, Daniele, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Bianchi, Maria Paola, additional, Volpetti, Stefano, additional, Trentin, Livio, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Carella, Angelo Michele, additional, Stefoni, Vittorio, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2017
Full Text
View/download PDF

35. Final Analysis of Overall Survival from the First Trial

Author

Facon, Thierry, primary, Dimopoulos, Meletios A, additional, Dispenzieri, Angela, additional, Catalano, John V., additional, Belch, Andrew, additional, Cavo, Michele, additional, Pinto, Antonello, additional, Weisel, Katja, additional, Ludwig, Heinz, additional, Bahlis, Nizar J., additional, Banos, Anne, additional, Tiab, Mourad, additional, Delforge, Michel, additional, Cavenagh, Jamie D., additional, Geraldes, Catarina, additional, Lee, Je-Jung, additional, Chen, Christine, additional, Oriol, Albert, additional, De La Rubia, Javier, additional, White, Darrell, additional, Binder, Daniel, additional, Lu, Jin, additional, Anderson, Kenneth C., additional, Moreau, Philippe, additional, Attal, Michel, additional, Fermand, Jean-Paul, additional, Avet-Loiseau, Herve, additional, Ervin-Haynes, Annette, additional, Chen, Guang, additional, Houck, Vanessa, additional, Hulin, Cyrille, additional, and Benboubker, Lofti, additional

Published
2016
Full Text
View/download PDF

36. Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Author

Pellegrini, Cinzia, primary, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Carlo-Stella, Carmelo, additional, Hohaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Gravetti, Angela, additional, Gritti, Giuseppe, additional, Arcari, Annalisa, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Naso, Virginia, additional, Volpetti, Stefano, additional, Visentin, Andrea, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Storti, Sergio, additional, Carella, Angelo Michele, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2016
Full Text
View/download PDF

37. Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Author

Broccoli, Alessandro, primary, Pulsoni, Alessandro, additional, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Santoro, Armando, additional, Hohaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Ronconi, Fioravante, additional, Gritti, Giuseppe, additional, Vallisa, Daniele, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Cavalieri, Elena, additional, Volpetti, Stefano, additional, Visentin, Andrea, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Carella, Angelo Michele, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2016
Full Text
View/download PDF

38. 90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Author

Lerch, Kristina, primary, Leng, Corinna, additional, Pinto, Antonello, additional, Linkesch, Werner, additional, Sill, Heinz, additional, Linden, Ola, additional, Viardot, Andreas, additional, Keller, Ulrich, additional, Hess, Georg, additional, Lastoria, Secondo, additional, Frigeri, Ferdinando, additional, Neik, Nicole, additional, Pott, Christiane, additional, Scholz, Christian W., additional, and Pezzutto, Antonio, additional

Published
2016
Full Text
View/download PDF

42. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma

Author

Luminari, Stefano, primary, Goldaniga, Maria, additional, Cesaretti, Marina, additional, Orsucci, Lorella, additional, Tucci, Alessandra, additional, Pulsoni, Alessandro, additional, Salvi, Flavia, additional, Arcaini, Luca, additional, Carella, Angelo Michele, additional, Tedeschi, Alessandra, additional, Pinto, Antonello, additional, Stelitano, Caterina, additional, and Baldini, Luca, additional

Published
2016
Full Text
View/download PDF

43. Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Author

Pinto, Antonello, primary, Pavone, Vincenzo, additional, Angrilli, Francesco, additional, Saggese, Mariangela, additional, Crisci, Stefania, additional, Patti, Caterina, additional, Zinzani, Pier Luigi, additional, D'Arco, Alfonso Maria, additional, Cavalieri, Elena, additional, Guarini, Attilio, additional, Spina, Michele, additional, Carlino, Daniela, additional, Falorio, Simona, additional, Morelli, Emanuela, additional, Arcamone, Manuela, additional, Frigeri, Ferdinando, additional, De Chiara, Annarosaria, additional, De Filippi, Rosaria, additional, and Corazzelli, Gaetano, additional

Published
2015
Full Text
View/download PDF

44. The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Author

De Filippi, Rosaria, primary, Crisci, Stefania, additional, Cillo, Michele, additional, Mele, Sara, additional, De Monaco, Angela, additional, Galati, Domenico, additional, Zanotta, Serena, additional, Capobianco, Gaetana, additional, Volzone, Francesco, additional, Arcamone, Manuela, additional, Maiolino, Piera, additional, Saggese, Mariangela, additional, Corazzelli, Gaetano, additional, Frigeri, Ferdinando, additional, Mehrling, Thomas, additional, and Pinto, Antonello, additional

Published
2015
Full Text
View/download PDF

45. Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

Author

De Filippi, Rosaria, primary, Cillo, Michele, additional, Crisci, Stefania, additional, Mele, Sara, additional, Zanotta, Serena, additional, De Monaco, Angela, additional, Galati, Domenico, additional, Iaccarino, Giancarla, additional, Di Francia, Raffaele, additional, Morelli, Emanuela, additional, Marcacci, Gianpaolo, additional, Becchimanzi, Cristina, additional, Guarini, Attilio, additional, Frigeri, Ferdinando, additional, Corazzelli, Gaetano, additional, and Pinto, Antonello, additional

Published
2015
Full Text
View/download PDF

46. Cancer and Anorexia Nervosa in the Adolescence: A Family-Based Systemic Intervention

Author

De Benedetta, Gabriella, Bolognini, Ida, D'Ovidio, Silvia, and Pinto, Antonello

Subjects
Article Subject, mental disorders
Abstract

Objective. Anorexia nervosa is difficult to diagnose in cancer patients since weight loss, aversion for food, and eating disturbances are frequent in patients undergoing chemotherapy and radiotherapy. Nevertheless, efforts are mandatory to recognize and manage this condition which may occur also in cancer patients with a special regard to adolescents. Methods. Through the clinical history of Anna, a 15-year-old adolescent with advanced cancer, we describe the effectiveness of a family-based systemic intervention to manage anorexia nervosa occurring in concomitance to osteosarcoma. Results. Through a two-year psychotherapy period involving different techniques applied to the whole family such as family genogram, family collage, and sculpture of family time, Anna was relieved from her condition. Conclusions. Upon early diagnosis and appropriate treatment, anorexia nervosa can be effectively approached in adolescent cancer patients. The presence of a life-threatening medical condition such as cancer may provide motivation for a patient to control disordered eating behavior in the context of an appropriate family-based systemic intervention. The general frame of anorexia occurring in cancer-bearing adolescents is reviewed and discussed.

Published
2011
Full Text
View/download PDF

48. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen

Author

Musso, Maurizio, primary, Messina, Giuseppe, additional, Di Renzo, Nicola, additional, Di Carlo, Paolo, additional, Vitolo, Umberto, additional, Scalone, Renato, additional, Marcacci, Gianpaolo, additional, Scalzulli, Potito R., additional, Moscato, Tiziana, additional, Matera, Rossella, additional, Crescimanno, Alessandra, additional, Santarone, Stella, additional, Orciuolo, Enrico, additional, Merenda, Anxur, additional, Pavone, Vincenzo, additional, Pastore, Domenico, additional, Donnarumma, Daniela, additional, Carella, Angelo M., additional, Ciochetto, Chiara, additional, Cascavilla, Nicola, additional, Mele, Anna, additional, Lanza, Francesco, additional, Di Nicola, Massimo, additional, Bonizzoni, Erminio, additional, and Pinto, Antonello, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results